HDAC9 and hydrops fetalis: That, paired with the FDA approval of four HDAC inhibitors (vorinostat, romidepsin, belinostat, and panobinostat) for the treatment of cancer, suggests feasibility in repurposing HDAC inhibitors for the treatment of human HF; there are currently no ongoing clinical trials using HDAC inhibitors in HF patients.